生物制药公司Silo Pharma Inc.宣布，其研发的Demerx NB新药已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。该药物以诺伊波加因（Noribogaine）为核心活性成分，旨在开发用于治疗酒精使用障碍（AUD）的新型疗法。
此次IND获批标志着该候选药物正式获准进入人体临床研究阶段，为推进其治疗酒精依赖的潜力迈出关键一步。公司表示将按计划开展后续临床试验，以评估Demerx NB的安全性与有效性。
生物制药公司Silo Pharma Inc.宣布，其研发的Demerx NB新药已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。该药物以诺伊波加因（Noribogaine）为核心活性成分，旨在开发用于治疗酒精使用障碍（AUD）的新型疗法。
此次IND获批标志着该候选药物正式获准进入人体临床研究阶段，为推进其治疗酒精依赖的潜力迈出关键一步。公司表示将按计划开展后续临床试验，以评估Demerx NB的安全性与有效性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.